Your session is about to expire
← Back to Search
Group I (SBRT) for Prostate Cancer
Study Summary
This trial is comparing two types of radiation therapy for treating patients with prostate cancer that has come back or has spread to a limited number of sites. One type, called stereotactic body radiation therapy (
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the enrollment process currently in progress for participants of this research study?
"According to the information provided on clinicaltrials.gov, this particular trial is not currently accepting new participants. The trial was first posted on February 9th, 2024 and was last updated on January 4th, 2024. However, it's worth noting that there are a total of 4933 other ongoing clinical trials actively recruiting participants at this time."
Has the United States Food and Drug Administration granted official approval to Group I (SBRT) treatment?
"Due to the availability of data supporting efficacy and multiple rounds of safety data, Group I (SBRT) has been assigned a safety rating of 3 by our team at Power."
Share this study with friends
Copy Link
Messenger